SEC Comment Letter 0000000000-25-003484 to ACTUATE THERAPEUTICS, INC. (ACTU)
ACTUATE THERAPEUTICS, INC.
Date: April 1, 2025 · CIK: 0001652935 · Accession: 0000000000-25-003484
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286201
Letter
Re: Actuate Therapeutics, Inc. Registration Statement on Form S-1 Filed March 28, 2025 File No. 333-286201 Dear Daniel Schmitt:
April 1, 2025
Daniel Schmitt President and Chief Executive Officer Actuate Therapeutics, Inc. 1751 River Run, Suite 400 Fort Worth, Texas 76107
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Janet Spreen, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 1, 2025 Daniel Schmitt President and Chief Executive Officer Actuate Therapeutics, Inc. 1751 River Run, Suite 400 Fort Worth, Texas 76107 Re: Actuate Therapeutics, Inc. Registration Statement on Form S-1 Filed March 28, 2025 File No. 333-286201 Dear Daniel Schmitt: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Janet Spreen, Esq. </TEXT> </DOCUMENT>